Health knowledge and news provided by doctors.

Ads by Google

Alzheimer's Disease

Alzheimer’s disease is one of the most challenging diseases of our time, and new research is being conducted all the time. The latest Alzheimer’s study results as well as information on prevention, treatment, caregiving, and respite can be found on Emaxhealth.

Minority Caregivers More Likely To Misinterpret Signs Of Alzheimer's

Hispanic and black caregivers are more likely than other ethnic groups to misinterpret symptoms of Alzheimer's disease as normal signs of aging, according to a recent survey by the Alzheimer's Foundation of America, HealthDay/Washington Post reports. The survey found that 37% of black caregivers and 33% of Hispanic caregivers believed that the disease's symptoms were a normal part of aging, compared with 23% of caregivers from other racial or ethnic groups.

The survey also found that black and Hispanic caregivers were more likely to report that they knew little about Alzheimer's disease.


Medivation's Dimebon Improved Thinking, Memory In Alzheimer's Patients

Alzheimer's patients treated with Medivation's investigational drug Dimebon showed improvement in the key aspects of cognitive function over a one-year period compared with placebo. The improvement occurred in not only memory and language, but also in more complex functions such as awareness of time and place, and praxis -- the process of getting an idea and initiating and completing a new motor task. These clinical results were generated during a pivotal trial of Dimebon in patients with mild-to-moderate Alzheimer's disease (AD).


Gammagard May Target Primary Pathway Involved In Alzheimer's Disease

A study demonstrates natural antibodies contained in GAMMAGARD LIQUID, a plasma-derived antibody replacement therapy indicated for primary immunodeficiency disorders and being studied in Alzheimer's disease, binds directly to multiple aggregated, or clustered, forms of the beta-amyloid peptide molecule.


Lilly Launches Trial For Treatment Of Alzheimer's Disease

Eli Lilly and Company starts a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the treatment of mild to moderate Alzheimer's disease. LY450139 is being tested to see if it can slow the progression associated with Alzheimer's disease by inhibiting gamma-secretase, an enzyme that can create a sticky protein called amyloid beta. Current Alzheimer's disease theory is that subtypes of amyloid beta clump together into plaques that eventually kill off brain cells.


Imaging Study Reveals Rapid Formation Of Alzheimer's-Associated Plaques

The amyloid plaques found in the brains of Alzheimer's disease patients may form much more rapidly than previously expected. Using an advanced microscopic imaging technique to examine brain tissue in mouse models of the devastating neurological disorder, researchers from the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND), working with colleagues from Washington University School of Medicine, find that plaques can develop in as little as a day and that Alzheimer's-associated neuronal changes appear soon afterwards. Their report will appear in the Feb. 7 issue of Nature.


Innovative Brain Scanning For Alzheimer's Unveiled

Researchers are launching an Alzheimer's screening clinical trial with Neuronetrix's innovative brain scanning system, called COGNISION. The study will involve brainwave assessments using a technology called event-related potentials (ERP's). The study is expected to validate the performance of the COGNISION system and to demonstrate the system's applicability in a primary care setting. Up to 100 Alzheimer sufferers and controls will participate over the next 6-12 months.


Study Demonstrates New Role For DHA In Alzheimer's Disease

In a recent pre-clinical study an omega-3 fatty acid found in algae called docosahexaenoic acid, or DHA, was found to decrease an important risk factor for late-onset Alzheimer's disease. Conducted at the University of California, Los Angeles using a mouse model, a diabetic rat model, and cultured human cells, the study found that DHA increases the production of LR11, a protein vital to clearing the brain of the enzymes that make the beta amyloid plaques that are thought to cause Alzheimer's disease. The investigators used Martek's DHA from microalgae for a portion of the research.


Anavex Advances Drug Candidate For Treatment Of Alzheimer's Disease

Anavex Life Sciences announces promising developments with ANAVEX 1-41, the company's lead drug candidate for Alzheimer's disease. In recent pre-clinical animal studies, ANAVEX 1-41 prevented oxidative stress, which damages and destroys cells and is believed to be a primary cause of Alzheimer's disease. ANAVEX 1-41 also prevented the expression of caspase-3, an enzyme that plays a key role in programmed cell death and in the loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory.